Leading pharmaceutical companies and total global vaccine revenue 2017 and 2024
Vaccine market overview
The vaccine market worldwide is expected to increase with a compound annual growth rate of seven percent between 2017 and 2024. A main driver of the growth is the increase of various infectious diseases like influenza, swine flu, hepatitis, tuberculosis, diphtheria, Ebola, and meningococcal and pneumococcal diseases. The United States are the world’s largest national market for vaccines, while North America is, accordingly, the largest regional market, followed by Europe. Vaccines which are administered intramuscularly make up over half of global revenues, while vaccines which are administered subcutaneously make up around one fifth of the market. Pfizer’s Prevnar 13 is currently the world’s top vaccine product, generating around 5.7 billion U.S. dollars of revenue.
The impact of vaccines
Originally, the main aim of vaccinations (immunizations) was to prevent infections from certain diseases and thus to reduce outbreaks and larger epidemics within the population. Thanks to vaccines, infectious diseases which once had high death rates like polio and smallpox have been nearly eradicated. Others, like measles, mumps, and whooping cough, are mostly under control. However, vaccines can also be used after an infection occurs as a therapeutic. Therapeutic vaccines in immuno-oncology are one of the latest big things in cancer treatment.